O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors

ACS Chemical Neuroscience

Volumn 3, Issue 5, 2012, Pages 418-426

  Niphakis, Micah J ^a   Johnson, Douglas S ^b   Ballard, T Eric ^b   Stiff, Cory ^b   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

2 arachidonoylglycerol; Activity based protein profiling; anandamide; carbamate; endocannabinoid; hydrolase

Indexed keywords

7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; CARBAMIC ACID DERIVATIVE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; HYDROLASE INHIBITOR; O HYDROXYACETAMIDE CARBAMATE DERIVATIVE; PF 7845; SA 57; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BEHAVIOR; BRAIN; CLICK CHEMISTRY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENCY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

2-ARACHIDONOYLGLYCEROL; ACTIVITY-BASED PROTEIN PROFILING; ANANDAMIDE; CARBAMATE; ENDOCANNABINOID; HYDROLASE;

AMIDOHYDROLASES; ANIMALS; CARBAMATES; ENDOCANNABINOIDS; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS;

RODENTIA;

EID: 84862091237     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200089j     Document Type: Conference Paper

References (55)

1. Ligresti, A., Petrosino, S., and Di Marzo, V. (2009) From endocannabinoid profiling to 'endocannabinoid therapeutics' Curr. Opin. Chem. Biol. 13, 321-331
2. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discovery 7, 438-455 (Pubitemid 351649182)
3. Fowler, C. J. (2008) "The tools of the trade"- an overview of the pharmacology of the endocannabinoid system Curr. Pharm. Des. 14, 2254-2265
4. Graham, E. S., Ashton, J. C., and Glass, M. (2009) Cannabinoid receptors: A brief history and "what's hot" Front. Biosci. 14, 944-957
5. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Chem. Rev. 108, 1687-1707 (Pubitemid 351796405)
6. Cravatt, B. F. and Lichtman, A. H. (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Curr. Opin. Chem. Biol. 7, 469-475 (Pubitemid 36980837)
7. Gaetani, S., Cuomo, V., and Piomelli, D. (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol. Med. 9, 474-478 (Pubitemid 37464283)
8. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., and Lichtman, A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 98, 9371-9376 (Pubitemid 32743923)
9. Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity J. Pharmacol. Exp. Ther. 311, 441-448 (Pubitemid 39391527)
10. Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., and Lichtman, A. H. (2011) The FAAH inhibitor PF-3845 acts in the nervous system to reverse lipopolysaccharide- induced tactile allodynia in mice. Br. J. Pharmacol., DOI: 10.1111/j.1476-5381. 2011.001445.x.
11. Lichtman, A. H., Shelton, C. C., Advani, T., and Cravatt, B. F. (2004) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia Pain 109, 319-327 (Pubitemid 38638709)
12. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., and Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9, 76-81 (Pubitemid 36098263)
13. Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., and Webb, M. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms Br. J. Pharmacol. 148, 102-113 (Pubitemid 43675605)
14. Russo, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., and Piomelli, D. (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice J. Pharmacol. Exp. Ther. 322, 236-242 (Pubitemid 46956375)
15. Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., and Lichtman, A. H. (2004) Functional disassociation of the central and peripheral fatty acid amide signaling systems Proc. Natl. Acad. Sci. U.S.A. 101, 10821-10826 (Pubitemid 38955826)
16. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., and Lutz, B. (2004) The endogenous cannabinoid system protects against colonic inflammation J. Clin. Invest. 113, 1202-1209 (Pubitemid 38544105)
17. Holt, S., Comelli, F., Costa, B., and Fowler, C. J. (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors Br. J. Pharmacol. 146, 467-476 (Pubitemid 41486689)
18. Naidu, P., Varvel, S., Ahn, K., Cravatt, B., Martin, B., and Lichtman, A. (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality Psychopharmacology 192, 61-70 (Pubitemid 46673891)
19. Moreira, F. A., Kaiser, N., Monory, K., and Lutz, B. (2008) Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54, 141-150 (Pubitemid 350299416)
20. Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., Tontini, A., Tarzia, G., Mor, M., Trezza, V., Goldberg, S. R., Cuomo, V., and Piomelli, D. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc. Natl. Acad. Sci. U.S.A. 102, 18620-18625 (Pubitemid 43011275)
21. Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavon, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., Lichtman, A. H., and Cravatt, B. F. (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5, 37-44
22. Long, J. Z., Nomura, D. K., and Cravatt, B. F. (2009) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism Chem. Biol. 16, 744-753
23. Long, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., Burston, J. J., Sim-Selley, L. J., Lichtman, A. H., Wiley, J. L., and Cravatt, B. F. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc. Natl. Acad. Sci. U.S.A. 106, 20270-20275
24. Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selley, D. E., Sim-Selley, L. J., Liu, Q. S., Lichtman, A. H., and Cravatt, B. F. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nat. Neurosci. 13, 1113-1119
25. Sciolino, N. R., Zhou, W., and Hohmann, A. G. (2011) Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2- arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats Pharmacol. Res. 64, 226-234
26. Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., and Ozaita, A. S. (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses Biol. Psychiatry 70, 479-486
27. Otrubova, K., Ezzili, C., and Boger, D. L. (2011) The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH) Bioorg. Med. Chem. Lett. 21, 4674-4685
28. Ahn, K., Johnson, D. S., and Cravatt, B. F. (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Expert Opin. Drug Discovery 4, 763-784
29. Koutek, B., Prestwich, G. D., Howlett, A. C., Chin, S. A., Salehani, D., Akhavan, N., and Deutsch, D. G. (1994) Inhibitors of arachidonoyl ethanolamide hydrolysis J. Biol. Chem. 269, 22937-22940 (Pubitemid 24283267)
30. Johnson, D. S., Stiff, C., Lazerwith, S. E., Kesten, S. R., Fay, L. K., Morris, M., Beidler, D., Liimatta, M. B., Smith, S. E., Dudley, D. T., Sadagopan, N., Bhattachar, S. N., Kesten, S. J., Nomanbhoy, T. K., Cravatt, B. F., and Ahn, K. (2010) Discovery of PF-04457845: A highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2, 91-96
31. Ahn, K., Smith, S. E., Liimatta, M. B., Beidler, D., Sadagopan, N., Dudley, D. T., Young, T., Wren, P., Zhang, Y., Swaney, S., Van Becelaere, K., Blankman, J. L. L., Nomura, D. K. K., Bhattachar, S. N., Stiff, C., Nomanbhoy, T. K., Weerapana, E., Johnson, D. S., and Cravatt, B. F. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain J. Pharmacol. Exp. Ther. 338, 114-124
32. Alexander, J. P. and Cravatt, B. F. (2005) Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes Chem. Biol. 12, 1179-1187 (Pubitemid 41628253)
33. Alexander, J. P. and Cravatt, B. F. (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases J. Am. Chem. Soc. 128, 9699-9704 (Pubitemid 44147953)
34. Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R. C., and Cravatt, B. F. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16, 411-420
35. Mileni, M., Kamtekar, S., Wood, D. C., Benson, T. E., Cravatt, B. F., and Stevens, R. C. (2010) Crystal Structure of Fatty Acid Amide Hydrolase Bound to the Carbamate Inhibitor URB597: Discovery of a Deacylating Water Molecule and Insight into Enzyme Inactivation J. Mol. Biol. 400, 743-754
36. Mileni, M., Johnson, D. S., Wang, Z., Everdeen, D. S., Liimatta, M., Pabst, B., Bhattacharya, K., Nugent, R. A., Kamtekar, S., Cravatt, B. F., Ahn, K., and Stevens, R. C. (2008) Structure-guided inhibitor design for human FAAH by interspecies active site conversion Proc. Natl. Acad. Sci. U.S.A. 105, 12820-12824
37. Tarzia, G., Duranti, A., Gatti, G., Piersanti, G., Tontini, A., Rivara, S., Lodola, A., Plazzi, P. V., Mor, M., Kathuria, S., and Piomelli, D. (2006) Synthesis and structure-activity relationships of FAAH inhibitors: Cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring ChemMedChem 1, 130-139 (Pubitemid 44104985)
38. Abouabdellah, A., Almario, G. A., Hoornaert, C., Lardenois, P., and Marguet, F. (2005) Aryl- and heteroaryl-piperidinecarboxylate derivatives, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies, US 2007/0021405, 31 pp, Sanofi-Synthelabo, France.
39. Leung, D., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2003) Discovering potent and selective reversible inhibitors of enzymes in complex proteomes Nat. Biotechnol. 21, 687-691 (Pubitemid 36638097)
40. Gelman, D. and Buchwald, S. L. (2003) Efficient palladium-catalyzed coupling of aryl chlorides and tosylates with terminal alkynes: use of a copper cocatalyst inhibits the reaction Angew. Chem., Int. Ed. 42, 5993-5996 (Pubitemid 38063504)
41. Jessani, N., Liu, Y., Humphrey, M., and Cravatt, B. F. (2002) Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness Proc. Natl. Acad. Sci. U.S.A. 99, 10335-10340
42. Patricelli, M. P., Giang, D. K., Stamp, L. M., and Burbaum, J. J. (2001) Direct visualization of serine hydrolase activities in complex proteome using fluorescent active site-directed probes Proteomics 1, 1067-1071 (Pubitemid 33696471)
43. Blankman, J. L., Simon, G. M., and Cravatt, B. F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol Chem. Biol. 14, 1347-1356 (Pubitemid 350257008)
44. Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., Bodor, A. L., Muccioli, G. G., Hu, S. S., Woodruff, G., Fung, S., Lafourcade, M., Alexander, J. P., Long, J. Z., Li, W., Xu, C., Moller, T., Mackie, K., Manzoni, O. J., Cravatt, B. F., and Stella, N. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors Nat. Neurosci. 13, 951-957
45. Ahn, K., Johnson, D. S., Fitzgerald, L. R., Liimatta, M., Arendse, A., Stevenson, T., Lund, E. T., Nugent, R. A., Nomanbhoy, T. K., Alexander, J. P., and Cravatt, B. F. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 46, 13019-13030 (Pubitemid 350086220)
46. Speers, A. E., Adam, G. C., and Cravatt, B. F. (2003) Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition J. Am. Chem. Soc. 125, 4686-4687 (Pubitemid 36505343)
47. Speers, A. E. and Cravatt, B. F. (2004) Profiling enzyme activities in vivo using click chemistry methods Chem. Biol. 11, 535-546 (Pubitemid 38511759)
48. Adibekian, A., Martin, B. R., Wang, C., Hsu, K.-L., Bachovchin, D. A., Niessen, S., Hoover, H., and Cravatt, B. F. (2011) Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors Nat. Chem. Biol. 7, 469-478
49. Johnson, D. S., Weerapana, E., and Cravatt, B. F. (2010) Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2, 949-964
50. Chang, J. W., Nomura, D. K., and Cravatt, B. F. (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis Chem. Biol. 18, 476-484
51. Bachovchin, D. A., Ji, T., Li, W., Simon, G. M., Blankman, J. L., Adibekian, A., Hoover, H., Niessen, S., and Cravatt, B. F. (2010) Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening Proc. Natl. Acad. Sci. U.S.A. 107, 20941-20946
52. Krishnasamy, S., Teng, A. L., Dhand, R., Schultz, R. M., and Gross, N. J. (1998) Molecular cloning, characterization, and differential expression pattern of mouse lung surfactant convertase Am. J. Physiol. 275, L969-975
53. Long, J. Z., Jin, X., Adibekian, A., Li, W., and Cravatt, B. F. (2010) Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases J. Med. Chem. 53, 1830-1842
54. Fay, L. K., Johnson, D. S., Lazerwith, S. E., Morris, M. A., Wang, L. J., Meyers, M. J., Kesten, S. R., and Stiff, C. M. (2008) Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors, WO 2008/047229, 126 pp, Pfizer Products Inc., USA.
55. Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999) Activity-based protein profiling: The serine hydrolases Proc. Natl. Acad. Sci. U.S.A. 96, 14694-14699 (Pubitemid 30019702)